http://purl.org/np/RAc2hHq09H... RAc2hHq09H

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-10T14:41:46.778Z

http://purl.org/np/RAc2hHq09H... RAc2hHq09H

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-10T14:41:46.778284

Elif Ozkan

2022-10-10T14:41:46.778Z

http://purl.org/np/RAc2hHq09H... RAc2hHq09H

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

LEXIVA is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. The protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that LexIVA plus ritonavir and lopinavir are clinically equivalent [see Clinical Studies (14.2)

Elif Ozkan

2022-10-10T14:41:46.778Z